EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan

Nimesh A Patel, Sandra Hoyek, Hasenin Al-Khersan, Nicolas A Yannuzzi, William E Smiddy

Ophthalmology Retina · 2024-11 · 8 (11) · 1061-1065

DOI: 10.1016/j.oret.2024.05.011 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2024-11. Verfasst von Nimesh A Patel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Massachusetts Eye and Ear and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Department of O…. Hauptthemen laut MEDLINE: Geographic Atrophy, Cost-Benefit Analysis, Intravitreal Injections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The purpose of this study was to evaluate the cost effectiveness of the treatment of geographic atrophy (GA) with intravitreal avacincaptad pegol (ACP) and to compare it with pegcetacoplan (PEG). DESIGN: Cost analysis based on data from published studies. SUBJECTS: None; based on data from published sham control compared with 2 treatment groups in each of the index studies. METHODS: Costs were based on 2022 Medicare reimbursement data for both facility (hospital-based) and nonfacility settings in Miami. Specific usage and outcomes were derived from the GATHER2 study as well as DERBY and OAKS trials. For ACP, all patients were treated every month (EM) in year 1 then randomized to every other month (EOM) or EM in year 2. Two-year models were created for patients in the facility setting for extrafoveal (ACP and PEG) and all patients (PEG). MAIN OUTCOME MEASURES: Cost, cost utility, and cost per area of GA (in United States dollars). RESULTS: The cost to treat GA with ACP in EM and EOM treatment groups over the 2 years as reported was $67 400 and $40 600, respectively. With ACP treatment over 2 years, the daily cost of delaying GA 3.4 months (EM) and 4.5 months (EOM) was $649 (EM) and $356 (EOM). The (facility-based) costs per unit area of retinal pigment epithelium saved for patients with extrafoveal GA over the 2-year period were $119 000/mm2 (EM ACP) versus $54 000/mm2 (EM PEG) (P < 0.001), $57 100/mm2 (EOM ACP) versus $31 400/mm2 (EOM PEG) (P < 0.001), and $45 300/mm2 (hypothetical EOM from outset ACP). CONCLUSION: Treatment of GA with intravitreal ACP EOM was more cost effective than EM. When assessing extrafoveal lesions, ACP was less cost effective than PEG for both EM and EOM treatment. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Geographic AtrophyCost-Benefit AnalysisIntravitreal InjectionsHumansVisual AcuityVascular Endothelial Growth Factor ATreatment OutcomeMaleFemaleAngiogenesis InhibitorsUnited StatesCost-Effectiveness Analysis

Stichwörter der Autor:innen

Age-related macular degenerationCost effectivenessGeographic atrophyLogistic growth

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Massachusetts Eye and Ear and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller…
  • Department of Ophthalmology, Massachusetts Eye and Ear and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
  • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: wsmiddy@med.miami.edu.

Zitieren

APA

Patel, N. A., Hoyek, S., Al-Khersan, H., Yannuzzi, N. A., & Smiddy, W. E. (2024). A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan. Ophthalmology Retina, 8(11), 1061-1065. https://doi.org/10.1016/j.oret.2024.05.011

Vancouver

Patel NA, Hoyek S, Al-Khersan H, Yannuzzi NA, Smiddy WE. A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan. Ophthalmology Retina. 2024;8(11):1061-1065. doi:10.1016/j.oret.2024.05.011

BibTeX
@article{Patel2024,
  author = {Patel, Nimesh A and Hoyek, Sandra and Al-Khersan, Hasenin and Yannuzzi, Nicolas A and Smiddy, William E},
  title = {A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan},
  journal = {Ophthalmology Retina},
  year = {2024},
  volume = {8},
  number = {11},
  pages = {1061--1065},
  doi = {10.1016/j.oret.2024.05.011}
}
Kostenlos starten →